36 results about "Oncotic pressure" patented technology

A composition and method for treating and preventing injury to central nervous system tissue are provided. The composition is comprised of agents that can increase colloidal osmotic pressure and osmolality. The method comprise of: a). Withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected and b). Injecting the composition into subarachnoid spaces.

The invention provides a method for preparing decellularized cornea. Due to the selection of components and proportions, colloid osmotic pressure of a decellularized cornea preparation liquid can be maintained by using a prepared protection liquid, and compared with a conventional decellularized cornea preparation liquid, the decellularized cornea preparation liquid is capable of remarkably alleviating the situation that the cornea transparency is degraded as an extracellular matrix such as collagen is excessively swelled and lost in the later cell treatment process; in addition, due to the addition of antibiotics such as tobramycin, bacterium propagation of susceptible cornea can be inhibited, and the contamination rate in the treatment process can be reduced. By adopting the method provided by the invention, cells can be crushed, and the situation that the trenchancy is degraded as cornea matrix collagen is damaged by long-term high pressure can be avoided. Secondly, as a detergent and nuclease act up simultaneously, cell debris and nucleic acid components can be relatively rapidly and effectively removed, and the situation that the trenchancy of the cornea is degraded as protein components such as cornea collagen are damaged in long-term treatment of the detergent and other components can be avoided.

A preparation method of narrow-distribution polymerized hemoglobin with low average molecular weight is characterized in that the method includes the following steps: {1} the hemoglobin is added into the gel retardation spectrum for balance through a pump and then distributively added with double-function crosslinker for polyreaction; {2} buffer solution is used to elute and collect the polymer produced in the step {1}, amide acid is used in the collected solution for stopped reaction and then hyperfiltration and concentration are carried out; {3} the obtained polymerized hemoglobin is treated by reduction by sodium borohydride and then is separated and purified through hyperfiltration and chromatography. The advantages of the present invention are that 1. the polymerized hemoglobin prepared by the present invention is narrow-distribution polymerized hemoglobin with low average molecular weight less than 200kD; 2. the present invention overcomes the poor homogeneity of the polymer in the traditional glutaraldehyde preparation method; 3. the polymerized hemoglobin is easily separated from the unpolymerized single hemoglobin and the reduced number of protein colloid decreases the osmotic pressure without any obvious change in viscosity.

Method and device for treatment of a heart after harvesting and before transplantation. The device includes a container intended to comprise the heart; a first line for connection to an aorta of the heart; a fluid circuit comprising an oxygenator for oxygenating said fluid and a heater/cooler for regulating the temperature of said fluid; and a pump for perfusion of said fluid through the coronary blood vessels of the heart. The fluid includes an oncotic agent exerting an oncotic pressure larger than about 30 mmHg; and is cardioplegic by comprising a potassium concentration, which is between 15 mM and 30 mM. A control device is arranged for controlling the pump to perform said perfusion intermittently, whereby the perfusion time is less than half of the cycle time. The perfusion is performed at a pressure, which is at least 15 mmHg and at least 15 mmHg lower than said oncotic pressure.

The invention provides an NK cell low-temperature preservation re-infusion liquid. According to the invention, a glucose and sodium chloride injection is added into the NK cell low-temperature preservation re-infusion liquid to serve as a diluent/buffer liquid, so that the effects of maintaining the pH value, the ion osmotic pressure and the colloid osmotic pressure and providing energy glucose for cells are achieved; the added human serum albumin can maintain the constant osmotic pressure of plasma colloid and supply nutrition; the added vitamin C can promote antibody and collagen formation and tissue repair, and meanwhile, the vitamin C also has the effects of resisting oxidation, resisting free radicals and inhibiting tyrosinase formation, so that the oxidative damage of cells can be reduced, and the accumulation of peroxides in the cells can be quickly relieved. According to the NK cell low-temperature preservation re-infusion liquid, the survival rate of NK cells can be kept at 80% or above after the NK cells are preserved for 48 h at the temperature of 4 DEG C, and a preparation can be directly re-infused.

The invention relates to a drug composition for treating encephaledema and a preparation method of the drug composition. The compound drug composition comprises the following active ingredients: sennoside A, cantharidin or a derivative of cantharidin, nimodipine or nifedipine, cinepazide maleate and edaravone. An active drug and a drug combination capable of reducing colloid osmotic pressure and crystal osmotic pressure in brain cells so as to treat the encephaledema are looked for through a cell experiment, and a novel pharmaceutical application is provided clinically.

The invention relates to cornea metaphase preserving fluid without a serum component. The cornea metaphase preserving fluid is prepared from an compound electrocular irrigating solution, sodium chloride, magnesium sulfate, monopotassium phosphate, chondroitin sulfate, sodium hyaluronate, a HEPES buffer solution, hydrochloric acid dexamethasone, reduced glutathione and levofloxacin. The cornea metaphase preserving fluid is reddish and transparent liquid with a specific electrolyte ionic concentration, a pH value, crystalloid osmotic pressure and colloid osmotic pressure. Needed raw materials are easy to get, the cornea metaphase preserving fluid does not contain the serum component, the risks of infecting special viruses is avoided, osmotic pressure of intracellular fluid and osmotic pressure of extracellular fluid are balanced through various ions, and the preservation effect is remarkable.

The invention relates to compositions suitable for plasma substitution comprising as a plasma expander a recombinant gelatin-like protein. Characteristic is that the gelatin-like protein can be a monomer or a polymer like a dimer, trimer or a tetramer of a human recombinant gelatin-like protein having an isolectric point of less than 8. The resulting gelatin-like proteins provide a method to control the clearance rate of a plasma expander by its molecular weight. Preferably the gelatin-like proteins have a low hydroxyproline content which prevents the composition from gelling and thus allows the use of high-molecular weight proteins in order to establish a suitable colloid osmotic pressure. An additional advantage of the gelatin-like proteins is that these avoid the risk of anaphylactic shock that exists in conjunction with the use of commercially available preparations.

A desalination system and method are based on the biological mechanism occurring in the mammalian kidney which utilizes colloid osmotic pressure and hydrostatic pressure to recover diluted salt solution from a concentrated one. The desalination system includes fluidly connected chamber compartments, one of which is filled with a charged substance, for example, a charged colloid polymer, to form a colloid salt solution when filled with the concentrated salt solution. Peripheral chamber compartments are filled with the concentrated salt solution. A system of semi-permeable membranes, not permeable to the charged substance, separate the chambers one from another. The system operates in the filling, equilibration, dilute, and collecting cycles which are controlled by opening and closing of the semi-permeable membranes. Desalination is based on the transfer of water due to osmotic pressure gradient across the membranes and is driven by hydrostatic pressure, thus providing energy efficient process. The charged substance is not consumed during the desalination and may be repeatedly used.

The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combination of oncotic and non-oncotic dextran molecules. The present invention also relates to the use of the priming solution in a cardiopulmonary bypass method, a method of maintaining oncotic pressure in a patient during a cardiopulmonary bypass procedure, and a combination of cardiopulmonary bypass priming solution and cardiopulmonary bypass apparatus.

The invention relates to an optimized anti-oxidative accelular protective solution, which has a critical effect on protection of structural completeness and biological nature of acellular tissues in the whole course of the decellularizing process. The protective solution is prepared from DMEM cellular culture medium L-histidine hydrochloride, allopurinol, chondroitin sulfate, low molecular dextran, hydroxypropyl methyl cellulose, HEPES buffer solution, dexamethason hydrochloride, reduced glutathione and levofloxacin. The protective solution is a light-red liquid with specific pH value, specific crystal and colloid osmotic pressure. The optimized anti-oxidative accelular protective solution is easily available in raw materials and economical in price, has strong applicability, wide application range and excellent anti-oxidation performance, and has a protective effect in the process of decellularizing biological tissues.

The invention discloses a cryopreservation solution and a cryopreservation method for long-term preservation of stem cells and stem cell products. The cryopreservation liquid is prepared from the following raw materials in parts by weight: 10 to 15 parts of low-molecular dextran, 2 to 8 parts of hydroxyethyl starch, 10 to 15 parts of chitosan, 3 to 6 parts of glycerol, 3 to 6 parts of dimethyl sulfoxide, 20 to 30 parts of glucose injection, 10 to 15 parts of compound amino acid injection and 20 to 30 parts of compound electrolyte injection. Under the combined action of the low-molecular dextran, the hydroxyethyl starch, the glucose injection, the compound amino acid injection and the compound electrolyte injection, the system balance of ion osmotic pressure and colloid osmotic pressure is maintained, an environmental condition beneficial to the survival of the stem cells is formed, and the long-term preservation of the stem cells is facilitated.